Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Ascendis Pharma A/S
ASND
$213.24
Name : Ascendis Pharma A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,028,571,136.00
EPSttm : -4.5
finviz dynamic chart for ASND
Ascendis Pharma A/S
$213.24
1.87%
$3.92

Float Short %

5.6

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

1.57

EPS Last/This Y

4.38

EPS This/Next Y

6.56

Price

209.48

Target Price

260.72

Analyst Recom

1.18

Performance Q

5.3

Relative Volume

0.34

Beta

0.45

Ticker: ASND




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-01ASND211.070.471.1616592
2025-12-02ASND202.670.500.4517123
2025-12-03ASND200.520.480.0216982
2025-12-04ASND208.530.460.1117492
2025-12-05ASND205.480.460.1417579
2025-12-08ASND206.120.470.2817602
2025-12-09ASND196.70.470.1317684
2025-12-10ASND201.490.460.0217965
2025-12-11ASND209.990.430.1419029
2025-12-12ASND220.710.400.3419868
2025-12-15ASND213.280.410.0620473
2025-12-16ASND212.010.410.3820801
2025-12-17ASND202.630.400.2320866
2025-12-18ASND199.850.400.0520907
2025-12-19ASND199.820.395.8321311
2025-12-22ASND209.430.180.0112432
2025-12-23ASND209.530.200.0413570
2025-12-26ASND209.10.190.1714457
2025-12-29ASND211.020.200.1714528
2025-12-30ASND209.610.200.4314688
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-01ASND210.8572.9375.9-3.38
2025-12-02ASND202.1672.9368.8-3.38
2025-12-03ASND200.5072.9375.6-3.38
2025-12-04ASND208.5772.9385.7-3.38
2025-12-05ASND205.4472.9374.5-3.38
2025-12-08ASND207.1272.9- -3.38
2025-12-09ASND196.6372.9367.4-3.38
2025-12-10ASND196.6372.9382.9-3.38
2025-12-11ASND210.1672.9386.6-3.38
2025-12-12ASND220.6278.3388.3-3.23
2025-12-15ASND213.2478.7371.4-3.23
2025-12-16ASND213.2478.7377.0-3.21
2025-12-17ASND202.4778.7368.9-3.21
2025-12-18ASND199.9278.7375.7-3.21
2025-12-19ASND199.8478.7378.8-3.21
2025-12-22ASND209.5578.7388.5-3.21
2025-12-23ASND209.2678.7378.7-3.21
2025-12-26ASND208.8977.7375.5-3.22
2025-12-29ASND211.1077.7381.8-3.22
2025-12-30ASND209.4877.7378.3-3.22
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-01ASND0.001.824.94
2025-12-02ASND0.001.824.94
2025-12-03ASND0.001.824.94
2025-12-04ASND0.001.824.94
2025-12-05ASND0.001.824.94
2025-12-08ASND0.001.824.94
2025-12-09ASND0.001.824.94
2025-12-10ASND0.001.825.45
2025-12-11ASND0.001.825.45
2025-12-12ASND0.001.825.45
2025-12-15ASND0.001.825.45
2025-12-16ASND0.001.825.45
2025-12-17ASND0.001.825.45
2025-12-18ASND0.001.825.45
2025-12-19ASND0.001.825.45
2025-12-22ASND0.001.835.45
2025-12-23ASND0.001.835.45
2025-12-26ASND0.001.835.60
2025-12-29ASND0.001.845.60
2025-12-30ASND0.001.845.60
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

Institutional Transactions

1.84

Beta

0.45

Average Sales Estimate Current Quarter

245

Average Sales Estimate Next Quarter

275

Fair Value

Quality Score

32

Growth Score

56

Sentiment Score

97

Actual DrawDown %

8.9

Max Drawdown 5-Year %

-60.5

Target Price

260.72

P/E

Forward P/E

48.35

PEG

P/S

17.75

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y​

-3.22

EPS Next Y. (Est.)

3.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

0.34

Return on Equity vs Sector %

106.5

Return on Equity vs Industry %

121.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

378.3
Ascendis Pharma A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading